Search

Your search keyword '"Insulin-Like Growth Factor Binding Protein 6 biosynthesis"' showing total 2 results
Start Over Descriptor "Insulin-Like Growth Factor Binding Protein 6 biosynthesis" Publisher lippincott williams & wilkins
2 results on '"Insulin-Like Growth Factor Binding Protein 6 biosynthesis"'

1. Myocardial insulin-like growth factor-I gene expression during recovery from heart failure after combined left ventricular assist device and clenbuterol therapy.

Author

Barton PJ, Felkin LE, Birks EJ, Cullen ME, Banner NR, Grindle S, Hall JL, Miller LW, and Yacoub MH

Subjects
Adrenergic beta-2 Receptor Agonists, Cardiomyopathy, Dilated complications, Cardiomyopathy, Dilated surgery, Chemokine CXCL12, Chemokines, CXC biosynthesis, Chemokines, CXC genetics, Combined Modality Therapy, Convalescence, Follow-Up Studies, Gene Expression Profiling, Heart Failure drug therapy, Heart Failure etiology, Heart Failure genetics, Heart Failure surgery, Humans, Insulin-Like Growth Factor Binding Protein 4 biosynthesis, Insulin-Like Growth Factor Binding Protein 4 genetics, Insulin-Like Growth Factor Binding Protein 6 biosynthesis, Insulin-Like Growth Factor Binding Protein 6 genetics, Insulin-Like Growth Factor I genetics, Insulin-Like Growth Factor II biosynthesis, Insulin-Like Growth Factor II genetics, Myocardium metabolism, Oligonucleotide Array Sequence Analysis, RNA, Messenger biosynthesis, Regeneration, Reverse Transcriptase Polymerase Chain Reaction, Stroke Volume, Ventricular Remodeling genetics, Adrenergic beta-Agonists therapeutic use, Clenbuterol therapeutic use, Heart Failure metabolism, Heart-Assist Devices, Insulin-Like Growth Factor I biosynthesis
Abstract

Background: Patients who undergo mechanical support with a left ventricular assist device (LVAD) exhibit reverse remodeling and in some cases recover from heart failure. We have developed a combination therapy using LVAD support combined with pharmacological therapy to maximize reverse remodeling, followed by the beta2 adrenergic agonist clenbuterol. We recently found that clenbuterol induces insulin-like growth factor I (IGF-I) in cardiac myocytes in vitro. The purpose of this study is to examine IGF-I expression in recovery patients after combination therapy., Methods and Results: Myocardial mRNA levels were determined by real-time quantitative polymerase chain reaction in 12 recovery patients (at LVAD implantation, explantation, and 1 year after explantation). IGF-I mRNA was elevated at the time of LVAD explantation relative to donors, with 2 groups distinguishable: Those with low IGF-I mRNA at implantation who showed significant increase during recovery and those with high IGF-I mRNA at implantation who remained high. Levels returned to normal by 1 year after explantation. Microarray analysis of implantation and explantation samples of recovery patients further revealed elevated IGF-II and IGF binding proteins IGFBP4 and IGFBP6. IGF-I levels correlated with stromal cell-derived factor mRNA measured both in LVAD patients and in a wider cohort of heart failure patients., Conclusions: The data suggest involvement of elevated myocardial IGF-I mRNA in recovery. IGF-I may act to limit atrophy and apoptosis during reverse remodeling and to promote repair and regeneration in concert with stromal cell derived factor.

Published
2005
Full Text
View/download PDF

2. Insulin-like growth factor binding protein-1-6 expression in activated microglia.

Author

Chesik D, Glazenburg K, Wilczak N, Geeraedts F, and De Keyser J

Subjects
Animals, Cells, Cultured, Gene Expression Regulation drug effects, Gene Expression Regulation physiology, Insulin-Like Growth Factor Binding Protein 1 biosynthesis, Insulin-Like Growth Factor Binding Protein 1 genetics, Insulin-Like Growth Factor Binding Protein 2 biosynthesis, Insulin-Like Growth Factor Binding Protein 2 genetics, Insulin-Like Growth Factor Binding Protein 3 biosynthesis, Insulin-Like Growth Factor Binding Protein 3 genetics, Insulin-Like Growth Factor Binding Protein 4 biosynthesis, Insulin-Like Growth Factor Binding Protein 4 genetics, Insulin-Like Growth Factor Binding Protein 5 biosynthesis, Insulin-Like Growth Factor Binding Protein 5 genetics, Insulin-Like Growth Factor Binding Protein 6 biosynthesis, Insulin-Like Growth Factor Binding Protein 6 genetics, Insulin-Like Growth Factor Binding Proteins genetics, Lipopolysaccharides pharmacology, Microglia drug effects, RNA, Messenger biosynthesis, RNA, Messenger genetics, Rats, Rats, Wistar, Insulin-Like Growth Factor Binding Proteins biosynthesis, Microglia metabolism
Abstract

In the CNS insulin-like growth factor-1 (IGF-1) enhances survival of neurons, promotes myelin synthesis and acts as a mitogen for microglia. The effects of IGF-1 are regulated by a family of 6 IGF binding proteins (IGFBPs). We investigated mRNA expression patterns of IGFBPs in primary rat microglia under basal conditions and after activation with lipopolysaccharide (LPS). Under basal conditions, microglia expressed IGFBP-2 to -6, whereas, IGFBP-1 could not be detected. Following 2 h treatment with LPS mRNA levels for IGFBP-4 and -6 displayed a down regulation, and IGFBP-5 became undetectable. Levels of IGFBP-2 and -3 remained unaltered. Expression patterns of IGFBPs might play an important role in regulating the autocrine/paracrine IGF-1 actions on microglia under inflammatory conditions.

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results